Ebola Virus Disease (EVD), formerly known as Ebola hemorrhagic fever, is a rare, highly lethal zoonotic illness affecting humans and nonhuman primates. Caused by viruses within the genus Ebolavirus in the family Filoviridae, EVD is characterized by acute fever, severe gastrointestinal distress, rapid systemic tissue breakdown, microvascular permeability, and, in severe cases, severe multi-organ failure and catastrophic hemorrhagic manifestations.
First recognized in 1976 during two simultaneous outbreaks in Nzara, Sudan, and Yambuku, Democratic Republic of the Congo (near the Ebola River), the virus gained global prominence during the massive West African epidemic of 2013–2016 and subsequent major outbreaks in Central Africa. EVD carries an average case fatality rate of approximately 50%, historically ranging from 25% to 90% depending on the specific viral species, host factors, and speed of supportive medical care.
Molecular Virology and Transmission Dynamics
The genus Ebolavirus comprises six distinct species, four of which cause severe disease in humans:
- Zaire ebolavirus (EBOV): The most virulent species, responsible for the largest outbreaks and highest mortality rates.
- Sudan ebolavirus (SUDV): Causes severe disease with fatality rates around 40%–55%.
- Bundibugyo ebolavirus (BDBV): Associated with smaller outbreaks and lower case fatality rates (~25%–35%).
- Tai Forest ebolavirus (TAFV): Documented in a single non-fatal human case.
Reservoir and Transmission Pathways
Fruit bats belonging to the Pteropodidae family serve as the natural reservoir for Ebola virus. Spillover events into human populations occur through direct contact with blood, secretions, organs, or bodily fluids of infected wild animals—such as fruit bats, chimpanzees, gorillas, or forest antelopes.
+--------------------------------------------------------------------------+
| EBOLA TRANSMISSION & DISSEMINATION |
| |
| Zoonotic Spillover ---> Human-to-Human Contact |
| (Contact with fruit bats (Direct contact with infected blood, |
| or wild game meat) vomitus, feces, or body fluids) |
| | |
| v |
| Widespread Organ Damage <--- Systemic Viral Dissemination |
| (Infection of monocytes/ (Inhibition of Type I interferon & |
| macrophages & endothelial cells) vascular endothelial breakdown) |
+--------------------------------------------------------------------------+
Human-to-human transmission occurs via direct physical contact (through broken skin or mucous membranes) with infected bodily fluids—including blood, vomitus, feces, saliva, urine, semen, and sweat—or surfaces contaminated with these fluids. Airborne transmission among humans has not been documented in natural settings. Nosocomial transmission and infection among healthcare workers operating without adequate Personal Protective Equipment (PPE) are significant drivers of epidemic spread.
Pathophysiology and Immune Evasion
Ebola virus possesses a single-stranded, negative-sense RNA genome encoding seven structural proteins. The virus exhibits tropism for monocytes, macrophages, dendritic cells, and endothelial cells.
Key Pathophysiological Mechanisms:
- Immune Evasion: The viral envelope glycoprotein (GP) and non-structural secreted glycoprotein (sGP) disrupt host defense mechanisms. The virus inhibits Type I interferon signaling, preventing infected cells from initiating an effective innate antiviral state.
- Pro-Inflammatory Cascade (“Cytokine Storm”): Productive infection of macrophages and monocytes triggers massive, uncontrolled release of pro-inflammatory cytokines—including Tumor Necrosis Factor-alpha (TNF-α\alphaα), Interleukin-6 (IL-6), and Interleukin-8 (IL-8).
- Vascular Permeability and Disseminated Intravascular Coagulation (DIC): Cytokine release combined with direct viral infection of endothelial cells causes extensive endothelial damage. This produces microvascular leakage, severe hypotension, hypovolemic shock, and widespread activation of the coagulation cascade, leading to consumption coagulopathy and uncontrollable bleeding.
Clinical Progression and Staging
The incubation period for EVD ranges from 2 to 21 days (typically 8 to 10 days). Individuals are not contagious until clinical symptoms appear.
| Disease Phase | Typical Timeline | Clinical Features & Symptom Profile |
|---|---|---|
| Early / Febrile Phase | Days 1–3 post-symptom onset | Abrupt onset of high fever, severe chills, generalized myalgias, arthralgias, severe headache, and profound malaise. |
| Gastrointestinal Phase | Days 4–7 post-symptom onset | Profuse watery diarrhea, severe vomiting, abdominal pain, anorexia, and odynophagia (painful swallowing). High risk of dehydration and electrolyte loss. |
| Severe / Multi-Organ Failure Phase | Days 7–10+ post-symptom onset | Metabolic acidosis, severe hypovolemic shock, renal failure, liver failure, altered mental status, and diffuse maculopapular rash. |
| Hemorrhagic Manifestations | Unfavorable cases | Petechiae, ecchymosis, mucosal bleeding (epistaxis, hematemesis, melena, gingival bleeding), and puncture-site oozing. |
Diagnostic Evaluation
Early identification of EVD is essential for infection control and prompt patient isolation:
- Reverse Transcription-Polymerase Chain Reaction (RT-PCR): The primary laboratory diagnostic standard for EVD. It detects viral RNA in whole blood or plasma with high sensitivity and specificity within a few days of symptom onset.
- Antigen-Capture ELISA: Useful for rapid detection of viral proteins in acute field settings where molecular testing capacity is limited.
- Serological Testing (IgM/IgG): Measures host antibody responses, useful during later stages of illness or retrospective epidemiological studies.
- Safety Precautions: Laboratory processing of suspected samples requires Biosafety Level 4 (BSL-4) containment standards or validated automated field assays operating under strict infection control measures.
Targeted Therapeutics and Supportive Care
The management of EVD has advanced from purely supportive care to targeted antiviral therapies and preventive vaccines:
1. Monoclonal Antibody Therapies
Single-target and combination monoclonal antibodies directed against the Ebola virus surface glycoprotein have demonstrated significant survival benefits:
- mAb114 (Ansuvimab): A single human monoclonal antibody that binds to the core receptor-binding domain of the Ebola glycoprotein, blocking host cell entry.
- REGN-EB3 (Atoltivimab / Maftivimab / Odesivimab): A combination of three human monoclonal antibodies that neutralize the Zaire ebolavirus by targeting distinct non-overlapping epitopes on the glycoprotein.
2. Comprehensive Supportive Care
Optimized supportive care significantly improves survival rates, even in the absence of specialized monoclonal antibodies:
- Aggressive Fluid Resuscitation: Replacing lost intravascular volume and electrolytes (sodium, potassium, bicarbonate) via intravenous access to correct severe dehydration and hypovolemic shock.
- Organ Support: Managing acute kidney injury via continuous continuous renal replacement therapy (CRRT) when available, alongside mechanical ventilation for respiratory failure.
- Empiric Antimicrobials: Administering broad-spectrum IV antibiotics to manage secondary bacterial translocation from compromised intestinal mucosa.
3. Immunization and Prevention
- rVSV-ZEBOV Vaccine (Ervebo): A recombinant vesicular stomatitis virus-vectored vaccine expressing the Zaire ebolavirus glycoprotein. It provides high protection against Zaire ebolavirus and is deployed via ring vaccination strategies during active outbreaks to protect contacts and frontline healthcare personnel.
Conclusion
Ebola Virus Disease remains a severe global public health threat due to its high lethality, rapid human-to-human transmission dynamics, and potential for severe disruption of health systems. Through a comprehensive understanding of its molecular biology, immune evasion mechanisms, diagnostic standards, and the deployment of effective monoclonal antibody treatments and preventive vaccines, global public health authorities can isolate cases rapidly, mitigate outbreak transmission, and improve clinical outcomes for affected patients.